Key points are not available for this paper at this time.
Patients with heart failure (HF) and iron deficiency are at increased risk of adverse clinical outcomes. We searched databases for randomised controlled trials that compared IV iron to placebo, in patients with HF with reduced ejection fraction (HFrEF). A total of 7,813 participants, all having HFrEF with 3,998 receiving IV iron therapy, and 3,815 control recipients were included. There was a significant improvement in Kansas City Cardiomyopathy Questionnaire favouring IV iron with MD 7.39, 95% CI 3.55, 11.22, p = 0.0002. Subgroup analysis, based on acute and chronic HF, has displayed a sustained statistical significance. Additionally, a significant increase in the left ventricular ejection fraction % was observed, with MD 3.76, 95% CI 2.32, 5.21, p < 0.00001. A significant improvement in 6-min walk test was noted, with MD 34.87, 95% CI 20.02, 49.72, p < 0.00001. Furthermore, IV iron showed significant improvement in NYHA class, peak VO
Awad et al. (Sun,) studied this question.